News | Stents | September 23, 2015

FDA OKs Second Randomized Trial for COBRA PzF Coronary Stent System

Second study will evaluate device’s ability to shorten dual antiplatelet therapy in patients at high risk of bleeding after PCI

CeloNova BioSciences, Cobra PzF coronary stent system, second randomized trial, COBRA-REDUCE

Cobra PzF coronary stent system image courtesy of CeloNova BioSciences Inc.

September 23, 2015 — CeloNova BioSciences Inc. announced that it has received conditional approval to start an investigational device exemption (IDE) trial to study the Cobra PzF coronary stent system in patients at high risk of bleeding. This is a second major interventional cardiology trial for CeloNova in the United States, following the successful enrollment of the PzF SHIELD clinical trial earlier this year.

This multicenter, prospective, randomized trial will be referred to as the COBRA-REDUCE trial. Prof. Adnan Kastrati, M.D., professor of medicine at ISAR Research Center, Munich, Germany, is the trial’s principal investigator.

The trial will evaluate if the Cobra PzF coronary stent, with its novel Polyzene-F nano-coating and advanced thin-strut design, can help reduce bleeding as compared to drug-eluting stents by shortening the duration of dual antiplatelet therapy (DAPT) to 14 days in patients treated with oral anticoagulation and undergoing percutaneous coronary intervention (PCI).

In February this year, CeloNova announced accelerated enrollment completion of its PzF SHIELD IDE trial, which will support regulatory submission for U.S. Food and Drug Administration (FDA) approval of the Cobra PzF stent.

The Cobra PzF coronary stent system received CE Mark approval in 2012 and launched in Europe and the Middle East in 2013.

For more information: www.celonova.com

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Overlay Init